6533b7ddfe1ef96bd1273d1b

RESEARCH PRODUCT

Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Henning Schulze-bergkamenElisabeth SchnoyDirk WaldschmidtStefan KubickaPatrick MichlChristoph KahlVolker EndrisHanno RiessArndt VogelKirsten MerxMichael GeisslerAndreas BlockStefan KasperMarkus MoehlerWilko WeichertJan KuhlmannMichael BitzerJens T. Siveke

subject

OncologyCancer Researchmedicine.medical_specialtyBiliary tract cancerbusiness.industryColorectal cancerGemcitabine/cisplatinmedicine.disease_causemedicine.diseaseOncologyInternal medicineMedicinePanitumumabKRASbusinessmedicine.drugEGFR inhibitors

description

4082 Background: Biliary tract cancer encompasses a group of genetically heterogeneous tumors. Panitumumab is a human EGFR inhibitor and has shown anti-tumor activity in RAS WT colorectal cancer. M...

https://doi.org/10.1200/jco.2015.33.15_suppl.4082